ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2014

A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.

Paul Monk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.